Literature DB >> 6400637

Histochemical approaches to steroid receptor analyses.

K S McCarty1, K S McCarty1.   

Abstract

Sex steroid receptor analysis is an important tool in clinical oncology. Various techniques are described including labelled ligand methodology, histochemical methods, and very promising immunohistochemical techniques using antireceptor monoclonal antibody. Approaches to data acquisition and analyses for these methods are discussed.

Mesh：

Substances：

Year:  1984        PMID： 6400637

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN： 0740-2570            Impact factor:   3.464


  19 in total

1.  The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.

Authors:  Maryam Althobiti; Abir A Muftah; Mohammed A Aleskandarany; Chitra Joseph; Michael S Toss; Andrew Green; Emad Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-06-10       Impact factor: 4.872

2.  Biological and clinical significance of PARP1 protein expression in breast cancer.

Authors:  Andrew R Green; Daniela Caracappa; Ahmed A Benhasouna; Alaa Alshareeda; Christopher C Nolan; R Douglas Macmillan; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2014-12-21       Impact factor: 4.872

3.  DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Authors:  Mohammed Aleskandarany; Daniela Caracappa; Christopher C Nolan; R Douglas Macmillan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res Treat       Date:  2015-02-19       Impact factor: 4.872

4.  Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration.

Authors:  Yang Zhang; Chenchen Yang; Mingsheng Zhang; Houli Liu; Chen Gong; Jie Zhang; Shanshan Xu; Jin Zou; Yuanzhong Kai; Yong Li
Journal:  Oncotarget       Date:  2017-11-18

5.  Phenotypic characterisation of breast cancer: the role of CDC42.

Authors:  Eleni Chrysanthou; Kylie L Gorringe; Chitra Joseph; Madeleine Craze; Christopher C Nolan; Maria Diez-Rodriguez; Andrew R Green; Emad A Rakha; Ian O Ellis; Abhik Mukherjee
Journal:  Breast Cancer Res Treat       Date:  2017-04-27       Impact factor: 4.872

6.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

Authors:  Rokaya El Ansari; Madeleine L Craze; Islam Miligy; Maria Diez-Rodriguez; Christopher C Nolan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res       Date:  2018-03-22       Impact factor: 6.466

7.  Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Authors:  Chitra Joseph; Olivia Macnamara; Madeleine Craze; Roslin Russell; Elena Provenzano; Christopher C Nolan; Maria Diez-Rodriguez; Sultan N Sonbul; Mohammed A Aleskandarany; Andrew R Green; Emad A Rakha; Ian O Ellis; Abhik Mukherjee
Journal:  Br J Cancer       Date:  2018-03-28       Impact factor: 7.640

8.  The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.

Authors:  Rokaya El Ansari; Madeleine L Craze; Maria Diez-Rodriguez; Christopher C Nolan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Br J Cancer       Date:  2018-03-16       Impact factor: 7.640

9.  PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

Authors:  Lutfi H Alfarsi; Rokaya El Ansari; Madeleine L Craze; Brendah K Masisi; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  BMC Cancer       Date:  2020-05-14       Impact factor: 4.430

10.  Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer.

Authors:  Lutfi H Alfarsi; Rokaya El Ansari; Brendah K Masisi; Ruth Parks; Omar J Mohammed; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.